ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the US for adult patients with HER2-positive early breast cancer ...
BMJ Open

Risk factors for cancer among the working population in China: a cross-sectional analysis of baseline data from the WECAN project

Objective This study aims to assess the prevalence of cancer risk factors in China’s working population and provide evidence for formulating more targeted workplace cancer prevention strategies.
Spectrum News NY1

Ranked-choice primary results to be released Tuesday

The ranked-choice tabulation is expected to add to Queens Assemblyman Zohran Mamdani's seven-point lead over former Gov. Andrew Cuomo Ranked choice will affect Manhattan's City Council District 4, ...